People interested in using telehealth services may also wish to consider alternative providers: Hims: This company specializes in male health and offers online consultations and personalized treatment plans, even for mental health conditions
Heart Health: Many people use it to manage their heart conditions or improve cardiovascular health
By selecting Klinic's services in Edwardsville, you are choosing insurance coverage management, prior authorization, and dedicated care
Weighing barely 150 milligrams, this tiny pine-cone-shaped structure sits deep in the center of your brain, tucked between the two hemispheres
Home Medical news & Guidelines Anesthesiology Cardiology and CTVS Critical Care Dentistry Dermatology Diabetes and Endocrinology ENT Gastroenterology Medicine Nephrology Neurology Obstretics-Gynaecology Oncology Ophthalmology Orthopaedics Pediatrics-Neonatology Psychiatry Pulmonology Radiology Surgery Urology Laboratory Medicine Diet Nursing Paramedical Physiotherapy Health news Fact Check Bone Health Fact Check Brain Health Fact Check Cancer Related Fact Check Child Care Fact Check Dental and oral health fact check Diabetes and metabolic health fact check Diet and Nutrition Fact Check Eye and ENT Care Fact Check Fitness fact check Gut health fact check Heart health fact check Kidney health fact check Medical education fact check Men's health fact check Respiratory fact check Skin and hair care fact check Vaccine and Immunization fact check Women's health fact check AYUSH State News Andaman and Nicobar Islands Andhra Pradesh Arunachal Pradesh Assam Bihar Chandigarh Chattisgarh Dadra and Nagar Haveli Daman and Diu Delhi Goa Gujarat Haryana Himachal Pradesh Jammu & Kashmir Jharkhand Karnataka Kerala Ladakh Lakshadweep Madhya Pradesh Maharashtra Manipur Meghalaya Mizoram Nagaland Odisha Puducherry Punjab Rajasthan Sikkim Tamil Nadu Telangana Tripura Uttar Pradesh Uttrakhand West Bengal Medical Education Industry Tirzepatide for Obesity: Highlights from the SURMOUNT-1 Trial - Video Overview The SURMOUNT-1 trial evaluated Tirzepatide a dual GIP/GLP1 agonist, in individuals with overweight (BMI more than or equal to 27 with a comorbidity) or obesity (BMI more than or equal to 30) without type 2 diabetes
Patients should be encouraged to report any suspected side effects via the MHRA Yellow Card Scheme
